WO2005116655A3 - Natriuretic compounds, conjugates, and uses thereof - Google Patents

Natriuretic compounds, conjugates, and uses thereof Download PDF

Info

Publication number
WO2005116655A3
WO2005116655A3 PCT/US2005/019249 US2005019249W WO2005116655A3 WO 2005116655 A3 WO2005116655 A3 WO 2005116655A3 US 2005019249 W US2005019249 W US 2005019249W WO 2005116655 A3 WO2005116655 A3 WO 2005116655A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
compounds
disclosed
natriuretic
modified
Prior art date
Application number
PCT/US2005/019249
Other languages
French (fr)
Other versions
WO2005116655A2 (en
Inventor
Kenneth D James
Balasingam Radhakrishnan
Navdeep B Malkar
Mark A Miller
Nnochiri N Ekwuribe
Original Assignee
Nobex Corp
Kenneth D James
Balasingam Radhakrishnan
Navdeep B Malkar
Mark A Miller
Nnochiri N Ekwuribe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nobex Corp, Kenneth D James, Balasingam Radhakrishnan, Navdeep B Malkar, Mark A Miller, Nnochiri N Ekwuribe filed Critical Nobex Corp
Priority to CA002568363A priority Critical patent/CA2568363A1/en
Priority to EP05780093A priority patent/EP1776132A4/en
Priority to AU2005248860A priority patent/AU2005248860A1/en
Priority to NZ552210A priority patent/NZ552210A/en
Priority to MXPA06013810A priority patent/MXPA06013810A/en
Priority to BRPI0511588-4A priority patent/BRPI0511588A/en
Priority to JP2007515532A priority patent/JP2008500375A/en
Publication of WO2005116655A2 publication Critical patent/WO2005116655A2/en
Publication of WO2005116655A3 publication Critical patent/WO2005116655A3/en
Priority to IL179521A priority patent/IL179521A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, and in some embodiments an improved half-life in circulation as compared to unmodified counterpart natriuretic compounds. Oral, parenteral, enteral, subcutaneous, pulmonary, and intravenous forms of the compounds and conjugates may be prepared as treatments and/or therapies for heart conditions particularly congestive heart failure. Modifying moieties comprising oligomeric structures having a variety of lengths and configurations are also disclosed. Analogs of the natriuretic compound are also disclosed, having an amino acid sequence that is other than the native sequence.
PCT/US2005/019249 2004-05-26 2005-05-26 Natriuretic compounds, conjugates, and uses thereof WO2005116655A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002568363A CA2568363A1 (en) 2004-05-26 2005-05-26 Natriuretic compounds, conjugates, and uses thereof
EP05780093A EP1776132A4 (en) 2004-05-26 2005-05-26 Natriuretic compounds, conjugates, and uses thereof
AU2005248860A AU2005248860A1 (en) 2004-05-26 2005-05-26 Natriuretic compounds, conjugates, and uses thereof
NZ552210A NZ552210A (en) 2004-05-26 2005-05-26 Natriuretic compounds, conjugates, and uses thereof
MXPA06013810A MXPA06013810A (en) 2004-05-26 2005-05-26 Natriuretic compounds, conjugates, and uses thereof.
BRPI0511588-4A BRPI0511588A (en) 2004-05-26 2005-05-26 natriuretic compounds and conjugates and their uses
JP2007515532A JP2008500375A (en) 2004-05-26 2005-05-26 Natriuretic compounds, complexes, and uses thereof
IL179521A IL179521A0 (en) 2004-05-26 2006-11-23 Natriuretic compounds, conjugates, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57443604P 2004-05-26 2004-05-26
US60/574,436 2004-05-26

Publications (2)

Publication Number Publication Date
WO2005116655A2 WO2005116655A2 (en) 2005-12-08
WO2005116655A3 true WO2005116655A3 (en) 2006-08-03

Family

ID=35451511

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/019249 WO2005116655A2 (en) 2004-05-26 2005-05-26 Natriuretic compounds, conjugates, and uses thereof

Country Status (14)

Country Link
US (3) US7648962B2 (en)
EP (1) EP1776132A4 (en)
JP (1) JP2008500375A (en)
KR (1) KR20070050876A (en)
CN (1) CN101027073A (en)
AU (1) AU2005248860A1 (en)
BR (1) BRPI0511588A (en)
CA (1) CA2568363A1 (en)
IL (1) IL179521A0 (en)
MX (1) MXPA06013810A (en)
NZ (1) NZ552210A (en)
RU (1) RU2388765C2 (en)
WO (1) WO2005116655A2 (en)
ZA (1) ZA200610700B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2403533A (en) * 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
EP2348114B1 (en) 2004-04-21 2018-07-25 Alexion Pharmaceuticals, Inc. Bone delivery conjugates and method of using same to target proteins to bone
ATE496060T1 (en) 2004-07-15 2011-02-15 Univ Queensland PROTEIN-TYPE COMPOUNDS AND APPLICATIONS THEREOF
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
AU2006330610B2 (en) * 2005-12-19 2012-08-16 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
US20080064045A1 (en) 2006-09-07 2008-03-13 Huaiqin Wu Biomarker fragments for the detection of human BNP
US20080181903A1 (en) * 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region
KR20080098216A (en) * 2007-05-04 2008-11-07 한미약품 주식회사 Natriuretic peptide conjugate using carrier substance
US20080280377A1 (en) * 2007-05-08 2008-11-13 Abbott Laboratories Human b-type natriuretic peptide assay having reduced cross-reactivity with other peptide forms
CA2693303C (en) * 2007-07-20 2017-11-07 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
PT2222697E (en) * 2007-11-01 2013-02-15 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
JP2011504506A (en) * 2007-11-21 2011-02-10 バイオマリン ファーマシューティカル インコーポレイテッド Variant of C-type natriuretic peptide
US20090286256A1 (en) * 2008-05-19 2009-11-19 Abbott Laboratories Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides
US20090286329A1 (en) * 2008-05-19 2009-11-19 Abbott Laboratoires Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides
US20110166063A1 (en) * 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of therapeutic peptides
EP2334335A1 (en) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of cd-np peptides
WO2010033221A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of protegrin peptides
PE20120792A1 (en) 2009-05-20 2012-07-27 Biomarin Pharm Inc TYPE C NATRIURETIC PEPTIDES VARIANTS
AU2010274293B9 (en) 2009-07-23 2013-08-29 Igisu Co., Ltd. Skin external-preparation composition
CN102548574B (en) 2009-09-25 2016-03-23 夏尔孤儿治疗有限公司 NPR-B agonist
TW201121995A (en) 2009-12-18 2011-07-01 Alcon Res Ltd Novel NPR-B agonists
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
EP2678002A2 (en) 2011-02-25 2014-01-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
CN102260345A (en) * 2011-05-17 2011-11-30 上海格尼生物技术有限公司 Preparation method for synthesizing human brain natriuretic peptide by solid phase polypeptide
CN107090028A (en) 2011-08-30 2017-08-25 梅约医学教育与研究基金会 Sharp sodium polypeptide
WO2013033675A1 (en) 2011-09-02 2013-03-07 Medtronic, Inc. Chimeric natriuretic peptide compositions and methods of preparation
WO2013070741A1 (en) * 2011-11-11 2013-05-16 Mayo Foundation For Medical Education And Research Methods and materials for regulating natriuretic polypeptide function
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2014209229A1 (en) * 2013-06-25 2014-12-31 National University Of Singapore Vasodilation peptides and uses thereof
CN105829350B (en) * 2013-12-17 2021-01-08 诺和诺德股份有限公司 Enterokinase cleavable polypeptides
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
BR112017011900A2 (en) 2014-12-05 2018-02-27 Alexion Pharma Inc treatment of recombinant alkaline phosphatase attacks
JP6868561B2 (en) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド How to treat subjects with alkaline phosphatase deficiency
AU2016272282A1 (en) * 2015-05-29 2018-01-25 Igisu Co., Ltd. Cyclic peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide
AU2016308624B2 (en) 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
AU2017205694B2 (en) * 2016-01-08 2022-05-26 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low NPR-C binding
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
CN109152820A (en) 2016-04-01 2019-01-04 阿雷克森制药公司 It is powerless with alkaline phosphatase enzyme treatment muscle
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
WO2018034622A1 (en) * 2016-08-18 2018-02-22 National University Of Singapore Peptides with vasodilatory and/or diuretic functions
AU2018243320A1 (en) 2017-03-31 2019-10-10 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (HPP) in adults and adolescents
RU2656188C1 (en) * 2017-05-03 2018-06-04 Общество с ограниченной ответственностью "Анкрим" (ООО "Анкрим") Synthetic analgesic means of peptide nature and method of its use
CA3075027A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Reversible linkers and use thereof
US11524033B2 (en) 2017-09-05 2022-12-13 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
US11905367B2 (en) 2018-03-20 2024-02-20 Nof Corporation Branched monodispersed polyethylene glycol, intermediate and methods for producing same
EP3773684A1 (en) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
KR102022118B1 (en) * 2019-01-07 2019-09-18 주식회사 아스트로젠 Serine derivative compound for the prevention or treatment of centralnervous system diseases
CN111848776B (en) * 2020-08-31 2022-03-18 江苏璟泽生物医药有限公司 Polyethylene glycol modified rhBNP and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219734A1 (en) * 2001-04-13 2003-11-27 Biosite Incorporated Polypeptides related to natriuretic peptides and methods of their identification and use
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US20060063699A1 (en) * 1998-03-09 2006-03-23 Larsen Bjarne D Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2410789C2 (en) * 1974-03-07 1980-08-07 Hoechst Ag, 6000 Frankfurt Process for cold grinding of cellulose derivatives
US4130647A (en) * 1977-07-08 1978-12-19 Pfizer Inc. Methods for treating congestive heart failure and ischemic heart disease
US4489065A (en) * 1981-07-02 1984-12-18 Valcor Scientific Ltd. Chondroitin drug Complexes
DE3378250D1 (en) * 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US5037741A (en) * 1986-08-18 1991-08-06 The Coca Cola Company Enzymatic method for the synthesis and separation of peptides
JP2544929B2 (en) * 1987-06-17 1996-10-16 第一化学薬品 株式会社 Novel bioactive peptide
CA1339210C (en) * 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5114923A (en) * 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
US20020086843A1 (en) * 1989-03-01 2002-07-04 Daiichi Pure Chemicals Co., Ltd. Physiologically active polypeptide and DNA
US5342940A (en) 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
US5108568A (en) 1989-07-07 1992-04-28 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Controlled method of reducing electrophoretic mobility of macromolecules, particles or cells
US5286637A (en) * 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
JP2665850B2 (en) * 1991-11-14 1997-10-22 塩野義製薬株式会社 Monoclonal antibody recognizing the C-terminus of hBNP
GB9211686D0 (en) * 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5512459A (en) * 1993-07-20 1996-04-30 Bionebraska, Inc. Enzymatic method for modification or recombinant polypeptides
US5569794A (en) * 1994-05-24 1996-10-29 Alliedsignal Inc. Vapor phase process for producing hydroflourocarbons from perchloroethylene having a phenolic inhibitor
US6037145A (en) * 1994-09-07 2000-03-14 Suntory Limited Process for production of protein
DE69509626T2 (en) * 1994-12-09 2000-01-13 Shionogi & Co Sandwich immunoassay for N-peptides
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
DK0914344T3 (en) 1996-03-04 2005-08-29 Scios Inc Assay and reagents for quantifying hBNP
US6028055A (en) * 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
WO1998045329A1 (en) 1997-04-04 1998-10-15 Novo Nordisk A/S Natriuretic peptide derivatives
US6495514B1 (en) 1998-01-21 2002-12-17 Mercer University Method for reducing inflammation and inducing an analgesic effect and compounds thereof
US6117644A (en) * 1998-06-04 2000-09-12 Ottawa Heart Institute Research Corporation Predicting and detecting cardiac allograft rejection
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
ES2180511T3 (en) 1999-01-26 2003-02-16 Lilly Co Eli MONODISPERSE FORMULATIONS OF HEXAMERIC INSULIN ANALOGS.
ES2257298T3 (en) 1999-05-17 2006-08-01 Conjuchem, Inc. PROTECTION OF ENDOGENOUS THERAPEUTIC PEPTIDES AGAINST THE ACTIVITY OF PEPTIDASE THROUGH CONJUGATION WITH BLOOD COMPONENTS.
WO2004011498A2 (en) 2002-07-31 2004-02-05 Conjuchem Inc. Long lasting natriuretic peptide derivatives
AU5043900A (en) * 1999-05-24 2000-12-12 Mayo Foundation For Medical Education And Research Adenovirus vectors encoding brain natriuretic peptide
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
KR100345214B1 (en) 1999-08-17 2002-07-25 이강춘 The nasal transmucosal delivery of peptides conjugated with biocompatible polymers
US6541508B2 (en) * 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6638906B1 (en) * 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
TWI249519B (en) * 2000-08-29 2006-02-21 Nobex Corp Immunoregulatory compounds and derivatives and methods of treating diseases therewith
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
PE20030536A1 (en) 2001-09-07 2003-07-03 Biocon Ltd METHODS FOR SYNTHESIZING INSULIN-OLIGOMER-POLYPEPTIDE CONJUGATES AND PROINSULIN-OLIGOMER-POLYPEPTIDE CONJUGATES AND METHODS OF SYNTHESIZING SUCH CONJUGATES
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
PL377813A1 (en) * 2002-11-26 2006-02-20 Biocon Limited Modified naturetic compounds, conjugates, and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063699A1 (en) * 1998-03-09 2006-03-23 Larsen Bjarne D Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US20030219734A1 (en) * 2001-04-13 2003-11-27 Biosite Incorporated Polypeptides related to natriuretic peptides and methods of their identification and use
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same

Also Published As

Publication number Publication date
IL179521A0 (en) 2007-07-04
EP1776132A4 (en) 2009-07-01
US20060172933A1 (en) 2006-08-03
MXPA06013810A (en) 2007-07-25
KR20070050876A (en) 2007-05-16
WO2005116655A2 (en) 2005-12-08
ZA200610700B (en) 2008-03-26
JP2008500375A (en) 2008-01-10
EP1776132A2 (en) 2007-04-25
CN101027073A (en) 2007-08-29
AU2005248860A1 (en) 2005-12-08
US7648962B2 (en) 2010-01-19
CA2568363A1 (en) 2005-12-08
BRPI0511588A (en) 2008-01-02
RU2006145827A (en) 2008-07-10
US20100216714A1 (en) 2010-08-26
NZ552210A (en) 2009-11-27
US20060074009A1 (en) 2006-04-06
RU2388765C2 (en) 2010-05-10

Similar Documents

Publication Publication Date Title
WO2005116655A3 (en) Natriuretic compounds, conjugates, and uses thereof
WO2004047871A3 (en) Modified naturetic compounds, conjugates, and uses thereof
WO2006076471A3 (en) Bnp conjugates and methods of use
JP2022062157A5 (en)
US20180016319A1 (en) Acylated Glucagon Analogues
US20180371045A1 (en) Novel insulin derivatives
TWI747929B (en) An acylation derivative of human insulin or analog thereof
WO2005058958A3 (en) Novel glp-1 analogues linked to albumin-like agents
KR20090098843A (en) Novel compounds and their effects on feeding behaviour
WO2007056362A3 (en) Glucagon analogs exhibiting physiological solubility and stability
MX2009002999A (en) Protease resistant insulin analogues.
IL177230A0 (en) Amylin family peptides and methods for making and using them
TW201204382A (en) An insulin conjugate using an immunoglobulin fragment
WO2003103572A3 (en) Modified glucagon-like peptide-1 analogs
WO2009158704A3 (en) Therapeutic agents comprising elastin-like peptides
NZ576470A (en) Analogs of ghrelin substituted at the n-terminal
JP2014501762A5 (en)
JP2008500375A5 (en)
CA2978043C (en) Peptides hormone analogues derivable from preproglucagon
RU2012109553A (en) MODIFIED VASOACTIVE INTESTINAL PEPTIDES
EP2287184A3 (en) Novel insulin derivatives
CN108352629A (en) Be electrically connected welding fixture
TW200502251A (en) Natriuretic compound conjugates, conjugates, and uses thereof
WO2007005056A3 (en) Platinum complexes with mononitrile-containing ligands
WO2009123567A3 (en) A connector claw

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 179521

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2568363

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/013810

Country of ref document: MX

Ref document number: 2007515532

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005248860

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005780093

Country of ref document: EP

Ref document number: 2006/10700

Country of ref document: ZA

Ref document number: 200610700

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 552210

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 7793/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020067027333

Country of ref document: KR

Ref document number: 2006145827

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2005248860

Country of ref document: AU

Date of ref document: 20050526

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005248860

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580025222.8

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005780093

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0511588

Country of ref document: BR